Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 9/20 | 0.50 |
| ▸ | ESR1 | P03372 | 6/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9284474 | 1.00 | ESR2 (0.50) | ESR2ESR1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL742590 | 0.86 | ESR2 (0.52) | ESR2ESR1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL11187439 | 0.86 | ESR2 (0.52) | ESR2ESR1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL11187444 | 0.86 | ESR2 (0.52) | ESR2ESR1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL9338782 | 0.86 | CYP2C9 (0.60) | ESR2ESR1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL9442518 | 0.86 | CYP2C9 (0.60) | ESR2ESR1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL16576984 | 0.85 | ESR2 (0.69) | ESR2ESR1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL27738543 | 0.85 | ESR2 (0.44) | ESR2ESR1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL9346799 | 0.85 | ESR2 (0.44) | ESR2ESR1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL21558838 | 0.82 | S1PR1 (0.40) | ESR2ESR1CYP2C9CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9234136-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2016-01-12 | — | — | US | disclosed |
| US-20140138581-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| CN-102464590-B | Immunomodulator and preparation method thereof as well as application thereof | SHANGHAI INST MATERIA MEDICA | 2013-10-23 | — | — | CN | disclosed |
| US-20130245067-A1 | DEUTERIUM-ENRICHED LENALIDOMIDE | DEUTERIA PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| CN-102464590-A | Immunomodulator and preparation method thereof as well as application thereof | SHANGHAI INST MATERIA MEDICA | 2012-05-23 | — | — | CN | disclosed |
| WO-1995010496-A1 | 2,3,4-TRIFLUOROBENZENES AND THEIR USE IN LIQUID CRYSTAL MIXTURES | MERCK PATENT GMBH (DE) | 1995-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245067-A1 | DEUTERIUM-ENRICHED LENALIDOMIDE | NR3C2, PDCD2L, REN | ESR2 3307/4885ESR1 3147/4885CYP2C9 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.